However, the overall safety profile of taspoglutide was clearly worse than exenatide with respect to gastrointestinal tolerability, systemic allergic reactions, and injection-site reactions.
Two-year data from a phase 3 trial of exenatide in Parkinson’s is due later this year and could help answer that question, said Prof Foltynie. Just as for previous schemes, metrics are being ...